Panelist discusses the current acceleration of new therapies for multiple myeloma. In the future, oncologists will be able to use CAR T and bispecific therapies more efficiently, and they will also have new tools including new CAR T therapies and bispecifics that will require less manufacturing time, have fewer AEs, and be more effective regarding the targeted disease.
Video content above is prompted by the following